About Us
We are pioneering the future of drug discovery.
Who We Are
Axcelead is your trusted drug discovery and development partner.
We were formed in 2017 as a Takeda spin-out with a singular vision in mind – to support healthcare innovation as the world’s most trusted drug discovery solutions provider. We bring our vision to life by harnessing our expertise and proven track record of success in small molecule, cell therapy and immune-oncology drug discovery to our partners to advance and improve their drug pipelines.
Mission & Vision
Mission
To be the most trusted companion to all who endeavor to bring highly innovative medicine to the world.
Vision
- Become the most sought-after solution provider of drug discovery to all corporate, start-up, academia, and public institutions
- Become the hub for drug discovery ecosystem that bridges foundational sciences to clinical developments
Our Company
Company: Axcelead Drug Discover Partners, Inc.
Founded: July 1, 2017
Location: 26-1, Muraoka-Higashi 2-chome
Fujisawa, Kanagawa 251-0012, Japan
Number of employees: About 240
Scope of business: Providing advisory and research services on drug discovery, etc.
Financial month: March
Capital: 100 million yen
History:
July 1, 2017: Commenced operations by inheriting the drug discovery platform of Takeda Pharmaceutical Company Limited.
April 1, 2019: Became a wholly owned subsidiary of Drug Discovery Gateway Investment Limited Partnership.
April 1, 2020: Transitioned to a holding company structure through a corporate split by incorporation.
Member of the Board:
Chairperson, Member of the Board: Yoshinori Ikeura
President & CEO: Kengo Okada
Board Member: Hiroki Maekawa
Board Member: Masamichi Sato
External Board Member: Victor Stone
Auditor: Fumiaki Masuko
Our Clients
